Terstegen L, Maassen B G, Radtke S, Behrmann I, Schaper F, Heinrich P C, Graeve L, Gatsios P
Institut für Biochemie, Linikum der RWTH Aachen, Pauvelsstr, 30, 52057 Aachen, Germany.
FEBS Lett. 2000 Jul 28;478(1-2):100-4. doi: 10.1016/s0014-5793(00)01826-3.
Prior activation of mitogen-activated protein kinases by phorbol 13-myristate 12-acetate (PMA) results in an inhibition of interleukin (IL)-6-induced activation of the Janus kinase/signal transducer and activator of transcription (STAT) signaling pathway which is most likely mediated by the induction of suppressor of cytokine signaling-3 and requires the specific SHP2 binding site Y759 of the IL-6 signal transducer gp130. In this study, we demonstrate that PMA inhibits STAT activation by IL-6 and the related cytokine leukemia inhibitory factor (LIF) but not by oncostatin M (OSM). Since the LIF receptor also contains an SHP2 recruitment site whereas the OSM receptor lacks such a module, we propose that two SHP2 binding modules within a homo- or heterodimeric receptor are necessary to mediate the PMA inhibitory effect.
佛波醇13-肉豆蔻酸酯12-乙酸酯(PMA)预先激活丝裂原活化蛋白激酶会导致白细胞介素(IL)-6诱导的Janus激酶/信号转导子和转录激活子(STAT)信号通路的激活受到抑制,这很可能是由细胞因子信号转导抑制因子-3的诱导介导的,并且需要IL-6信号转导子gp130的特定SHP2结合位点Y759。在本研究中,我们证明PMA抑制IL-6和相关细胞因子白血病抑制因子(LIF)诱导的STAT激活,但不抑制制瘤素M(OSM)诱导的STAT激活。由于LIF受体也含有一个SHP2招募位点,而OSM受体缺乏这样一个模块,我们提出同型或异型二聚体受体中的两个SHP2结合模块对于介导PMA抑制作用是必需的。